136 related articles for article (PubMed ID: 29758343)
1. The effect of the composition of a fixed dose combination on bioequivalence results.
Šalandová J; Franc A; Hofmann J; Dumicic A; Kukačková L; Červená T; Beránek J; Srbek J; Repický A; Vladovičová B; Vetchý D
Int J Pharm; 2018 Jul; 546(1-2):235-246. PubMed ID: 29758343
[TBL] [Abstract][Full Text] [Related]
2. Evaluating bioequivalence of meloxicam tablets: is in-vitro dissolution test overdiscriminating?
Jin C; Zhao C; Shen D; Dong W; Liu H; He Z
J Pharm Pharmacol; 2018 Feb; 70(2):250-258. PubMed ID: 29193077
[TBL] [Abstract][Full Text] [Related]
3. Powdered self-emulsified lipid formulations of meloxicam as solid dosage forms for oral administration.
Agarwal V; Alayoubi A; Siddiqui A; Nazzal S
Drug Dev Ind Pharm; 2013 Nov; 39(11):1681-9. PubMed ID: 23072611
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and bioequivalence of 2 meloxicam oral dosage formulations in healthy adult horses.
Vivancos M; Barker J; Engbers S; Fischer C; Frederick J; Friedt H; Rybicka JM; Stastny T; Banse H; Cribb AE
Can Vet J; 2015 Jul; 56(7):730-6. PubMed ID: 26130835
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of meloxicam administered as regular and fast dissolving formulations to the rat: influence of gastrointestinal dysfunction on the relative bioavailability of two formulations.
Aghazadeh-Habashi A; Jamali F
Eur J Pharm Biopharm; 2008 Nov; 70(3):889-94. PubMed ID: 18715548
[TBL] [Abstract][Full Text] [Related]
6. Omeprazole--a new formulation.
Armstrong D
Can J Gastroenterol; 1997; 11(8):655-6. PubMed ID: 9459043
[No Abstract] [Full Text] [Related]
7. The influence of polymorphism on the manufacturability and in vitro dissolution of sulindac-containing hard gelatin capsules.
Guadalupe Sánchez-González E; Yépez-Mulia L; Jesús Hernández-Abad V; Jung Cook H
Pharm Dev Technol; 2015 May; 20(3):306-13. PubMed ID: 24417644
[TBL] [Abstract][Full Text] [Related]
8. Improved absorption of meloxicam via salt formation with ethanolamines.
Han HK; Choi HK
Eur J Pharm Biopharm; 2007 Jan; 65(1):99-103. PubMed ID: 16919925
[TBL] [Abstract][Full Text] [Related]
9. Bioequivalence and pharmacokinetic study of two different omeprazole capsule formulations in healthy Bangladeshi volunteers.
Joti JJ; Nahar K; Hasan A; Azad MA; Ullah MA; Islam SM; Hasnat A
Arzneimittelforschung; 2009; 59(4):171-5. PubMed ID: 19517893
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics of meloxicam.
Türck D; Busch U; Heinzel G; Narjes H
Arzneimittelforschung; 1997 Mar; 47(3):253-8. PubMed ID: 9105543
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic and bioequivalence study of meloxicam tablets in healthy male subjects.
Gschwend MH; Erenmemişoğlu A; Martin W; Tamur U; Kanzik I; Hincal AA
Arzneimittelforschung; 2007; 57(5):264-8. PubMed ID: 17598697
[TBL] [Abstract][Full Text] [Related]
12. Bioequivalence study of a novel orodispersible tablet of meloxicam in a porous matrix after single-dose administration in healthy volunteers.
Radicioni M; Connolly S; Stroppolo F; Granata G; Loprete L; Leuratti C
Int J Clin Pharmacol Ther; 2013 Mar; 51(3):234-43. PubMed ID: 23380429
[TBL] [Abstract][Full Text] [Related]
13. Physiologically Based Biopharmaceutics Modeling for Gefapixant IR Formulation Development and Defining the Bioequivalence Dissolution Safe Space.
Wang M; Heimbach T; Zhu W; Wu D; Reuter KG; Kesisoglou F
AAPS J; 2024 Jun; 26(4):69. PubMed ID: 38862807
[TBL] [Abstract][Full Text] [Related]
14. Effect of the formulation on the bioequivalence of meloxicam: tablet and suspension.
Helmy SA; El Bedaiwy HM
Drug Res (Stuttg); 2013 Jul; 63(7):331-7. PubMed ID: 23619819
[TBL] [Abstract][Full Text] [Related]
15. Bioequivalence in dogs of a meloxicam formulation administered as a transmucosal oral mist with an orally administered pioneer suspension product.
Lees P; Cheng Z; Keefe TJ; Weich E; Bryd J; Cedergren R; Cozzi E
J Vet Pharmacol Ther; 2013 Feb; 36(1):78-84. PubMed ID: 22533512
[TBL] [Abstract][Full Text] [Related]
16. Generic omeprazole delayed-release capsules: in vitro performance evaluations.
Moore T; Smith A; Ye W; Toler DY; Westenberger BJ; Lionberger R; Raw A; Yu L; Buhse LF
Drug Dev Ind Pharm; 2009 Aug; 35(8):917-21. PubMed ID: 19555236
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics during treatment with the omeprazole 20 mg enteric-coated tablet and 20 mg capsule in asymptomatic duodenal ulcer patients.
Thomson AB; Kirdeikis P; Lastiwka R; Röhss K; Sinclair P; Olofsson B
Can J Gastroenterol; 1997; 11(8):657-60. PubMed ID: 9459044
[TBL] [Abstract][Full Text] [Related]
18. Bioequivalence assessment of two capsule formulations of omeprazole in healthy volunteers.
Hussein RF; Lockyer M; Hammami MM
Arzneimittelforschung; 2007; 57(2):101-5. PubMed ID: 17396620
[TBL] [Abstract][Full Text] [Related]
19. Development of meloxicam in situ implant formulation by quality by design principle.
Ibrahim HM; Ahmed TA; Hussain MD; Rahman Z; Samy AM; Kaseem AA; Nutan MT
Drug Dev Ind Pharm; 2014 Jan; 40(1):66-73. PubMed ID: 23298324
[TBL] [Abstract][Full Text] [Related]
20. Soft, chewable gelatin-based pharmaceutical oral formulations: a technical approach.
Dille MJ; Hattrem MN; Draget KI
Pharm Dev Technol; 2018 Jun; 23(5):504-511. PubMed ID: 28532266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
